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New Haven, CT. 
 
Abstract: 
Melanoma is a prevalent, deadly disease with poor outcomes following 
metastasis.  It is an immunogenic cancer with many unique tumor antigens, but the tumor 
microenvironment inhibits the immune system.  Current monoclonal antibody treatment 
has been shown to be beneficial in metastatic melanoma by blocking inhibitory immune 
signals such as PD-1 or CTLA-4.  The expression of immunostimulatory proteins such as 
B7.1 by tumor cells could provide additional immune targeting.  Viral vectors based on 
the parvovirus genome could efficiently and selectively express B7.1 in melanoma cells, 
such that they become competent to directly activate cognate T cells.  Once activated, T 
cells will become armed as cytotoxic effectors against cells expressing melanoma tumor 
antigens. To generate a viral vector, we first needed a parvovirus that infected melanoma.  
Parvoviruses are uniquely adapted to infect tumor cells as viral replication is dependent 
on the host cell advancing through S phase.  However, most parvoviruses tested were 
unable to establish infection in the murine melanoma cell line B16F10.  The most 
infectious parvovirus in B16F10 was mouse parvovirus 1a (MPV1a).  B16F10 cells were 
infected with MPV1a, and the progeny virus was harvested and used to re-infect more 
B16F10 cells.  After five serial passages of virus, the mutant polyclonal stock named 
MPV P5 was analyzed.  At 24 hours following infection at a multiplicity of 5000 virions 
per cell, MPV1a infected 16% of cells, whereas MPV P5 infected 74%.  Construction of 
a molecular clone from the polyclonal MPV P5 mixture yielded a construct consisting of 




of cells under the same conditions.  The mutations that were most responsible for the 
increase in B16F10 infectivity were isolated to the VP2 region, which encodes the major 
capsid protein.  By incorporating the viral proteins from the clonal version of MPV P5 
into a parvoviral vector system, we have generated a vector capable of transducing 
B16F10 cells and simultaneously expressing the Green Fluorescent Protein marker and 
B7.1.  Further experiments are needed to determine if the B7.1 expression is sufficient at 
its current rate of infectivity to modulate an immune response, and to examine whether 
viral products within the tumor cells generate additional immunogenic signaling.  Other 
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Approaches to Melanoma Therapy 
 Melanoma is a deadly form of cancer that metastasizes easily without detection 
and becomes incredibly difficult to treat.  In 2015, the American Cancer Society expects 
73,870 new cases of melanoma with 9,940 projected deaths (1).  Before the advancement 
of monoclonal antibody treatments for metastatic melanoma, treatment was limited to 
decarbazine and interleukin-2.  Recently, inhibitors against BRAF and mitogen-activated 
protein kinase kinase (MEK) have been shown in the clinic to suppress tumor growth.  
New monoclonal antibodies are targeted at deconstructing the immune evasion signals 
that melanoma evokes for survival.  In the realm of immunotherapy, as summarized in 
Figure 1 (2), the CTLA-4 inhibitor ipilimumab is currently approved for melanoma 
treatment, along with interleukin-2 and interferon.  Signaling mechanisms currently being 
targeted in this way include inhibiting programmed cell death receptor (PD-1), activating 
CD27 (TNF stimulatory receptor on T cells), inhibiting B7-H3 (possible B7 inhibitory 
signal), inhibiting phosphatidylserine exposed on the outer surface of the cell membrane, 
and increasing granulocyte macrophage colony stimulating factor.  Another aspect of 
immunotherapy is being addressed by the development of cancer vaccines, using 
antigenic proteins from melanoma, such as melanoma antigen-1 (MAGE1), GP100, 
Melan A, NY-ESO, or autologous tumor lysates to stimulate the immune system.  The 
remaining immunotherapy under investigation is adoptive T cell therapy, where 
lymphocytes found invading the tumor are removed, expanded, and returned in much 






This project aims to complement some of these immunotherapeutic approaches by 
developing a parvoviral vector that expresses B7.1/CD80 in melanoma cells to generate 
its proposed immunostimulatory effect (Figure 1).  B7.1 is part of the B7 family of 
ligands that are involved in stimulatory and inhibitory immune signaling.  In the 
canonical sense, antigen presenting cells (APCs) present an antigen on MHC to the T cell 
receptor (TCR) of a naïve T cell.  This interaction is reinforced by B7.1 on the APC 
binding to the CD28 receptor on the naïve T cell leading to increased proliferation and 
induction of the cytotoxic T cell phenotype in an activation process known as co-
stimulation.  As the T cell matures, it switches to express the inhibitory receptor CTLA-4 
(cytotoxic T-lymphocyte-associated protein 4), which binds to B7.1 with a higher affinity 
 
 
Figure 1 – Summary of Cancer Immunotherapies 
 
Multiple interactions exist between tumor cells, T-cells, and dendritic cells (DCs) that 
modulate the immune response to cancer cells.  Current receptors and medications are 




than CD28, and thus limits CD28’s proliferative signaling.  Other ligands found on tumor 
cells can also modulate the growth and activity of T cells.  Programmed death ligand 1 
(PDL-1) is another immune signal commonly found on tumor cells and binds the PD-1 
receptor on activated T cells in peripheral tissues.  This event is a late inhibition of 
activated T cells as compared to the early inhibition of function by CTLA-4.  Expression 
of PDL-1 is a negative prognostic factor for survival (3). 
The idea of using B7.1 expression in cancer cell lines has been promising in 
previous studies.  The administration of non-replicating immunogenic tumor cells 
expressing B7.1 increased survival against future tumor challenges when B7.1 was 
expressed (4).  The human melanoma cell line Me1B6 leads to increased lymphocytic 
cytotoxic activity and cytokine release when expressing B7.1 (5).  UV-induced 
melanoma K1735 expressing B7.1 leads to a 90-day immunity against re-challenge in 
mice (6).  The response to B7.1-expressing tumor cells can be augmented by co-treating 
with IL-12 to improve activity against poorly immunogenic tumor types (7).  B7.1 
expression has been shown to overcome the protective effect of tumor cells expressing 
PDL-1 on the surface (8).  Given the previous success of B7.1 in melanoma, we would 
like to use a parvoviral delivery system to express B7.1 in tumor cells, so that the B7.1 
can activate T cells to become cytotoxic effectors and the viral proteins can increase the 







The Genetic Strategy of Parvoviruses 
 Parvoviruses are single-stranded, non-enveloped DNA viruses.  The genome is 
quite small, approximately five kilobases in length.  Two tandemly arranged gene 
cassettes encode for the nonstructural (NS) proteins and viral capsid proteins (VP).  
Splicing of the major intron allows for two major non-structural proteins variants, known 
as NS1 and NS2, as shown in Figure 2 (9).  Alternative splicing within the central, minor 
intron region generates two VP gene products, VP1 and VP2, which differ at their N-
termini by the inclusion of a 142 amino acid peptide called the VP1 specific region 
(VP1SR).  The minor intron alternative splicing also generates three isoforms of NS2 that 
differ in their C-terminal hexapeptides.  At the end of the VP2 gene there is a 3’ 
untranslated region (UTR) that, in some viruses, contains internal repeats.  Infection 
occurs when the virus enters the cell and the viral genome is converted into double-
stranded DNA in the nucleus, allowing transcription from the initiating P4 promoter, 
leading to production of NS1 and NS2 as early nonstructural proteins.  Accumulation of 
NS1 will then lead to production of VP1 and VP2 capsid proteins from the P38 promoter.  
The genome is amplified through a process of rolling hairpin replication, in which 
hairpins on the ends of the single-stranded genome self-prime the genome for extension 
by host cell polymerases.  This process continues unidirectionally to produce double-
stranded multimeric intermediates that are cleaved into monomer lengths from which 
single-stranded genomic units are "peeled off" for packaging.  Once the viral genome is 







Parvoviruses lack an intrinsic process for initiating the conversion of their packed 
single-stranded DNA into double-stranded DNA, and until the cell progresses through S 
phase, the genome appears to remain sequestered in the capsid and incapable of 
transcription.  Unlike other DNA viruses, the parvoviruses do not possess any early-
acting ancillary proteins that can coax the non-cycling host cell into S phase, so they must 
wait until the cell prepares to divide (11), thus they are innately primed to replicate in 
rapidly-dividing cells, making them uniquely suited for targeting malignancy. 
 
 
Figure 2 – Rodent Parvovirus Gene Products, Reading Frames, and Splicing 
 
This figure demonstrates the genetic organization of parvoviruses adapted from 
Cotmore et al (9).  Non-structural protein 1 (NS1) is located within the first reading 
frame.  Three splicing variants of NS2 are in the second reading frame.  Two splicing 
variants of the VP gene are in the third reading frame and produce the capsid.  The P4 
promoter drives the production of NS1/NS2, while NS1 drives the P38 promoter to 




However, the mechanism(s) underlying the inherent oncotropism of parvoviruses 
are more complex than the S phase requirement, which can be met by any dividing cell.  
Current research indicates that normal human cells are able to suppress rodent parvoviral 
infection while transformed cells lose that ability.  In infections with the most intensely 
studied prototype parvovirus Minute Virus of Mice (MVMp), transformed A9 mouse 
fibroblasts fail to express type 1 interferon and become infected, while non-transformed 
murine embryonic fibroblast precursors do release interferon to combat infection (12).  
However, this observation cannot be extrapolated to human cells, since other studies have 
shown that interferon does not affect parvoviral infection in either normal or transformed 
human cells (13, 14).   
The idea of using viruses to treat cancer is not new.  Originally, the goal was to 
use oncolytic viruses to directly lyse the malignant cells.  Cervical cancer regression was 
seen with rabies infections in 1912 and clinical trials treated cervical cancer with 
adenovirus with moderate success in 1954 (15).  The most current oncolytic treatment of 
melanoma with viruses uses herpesvirus or coxsackie virus engineered for cancer cell 
specificity and GM-CSF expression in the tumor (16).  Treatment ideas have shifted as 
technology advanced and gene delivery via viral vectors became possible.  Propagating, 
infectious particles can be replaced with highly-engineered vector systems.  These vector 
systems remove the fear of propagation and allow the expression of transgenes, as 





Development of Parvoviral Vectors 
Autonomously replicating parvoviral vectors (Figure 3) can be produced with 
transgenes up to ~2.5kb in length and can be supplied with modified capsids to influence 
tissue specificity (17).  They can provide transient gene transduction in dividing cells 
with low risks for unintended consequences due to their inherent oncotropism and lack of 
viral incorporation into cellular DNA (18).  The lack of human immunity to rodent 
parvoviruses means that the vectors will not be immediately inactivated by preexisting 




Figure 3 – The Original Autonomous Parvoviral Vector System 
 
The vector plasmid has an early stop codon at the start of truncated VP1 so no capsid 
proteins are expressed.  The transgene fits into the remaining space from the VP1 
truncation.  VP2 stuffer sequence is added as needed to bring the overall construct 
length into the appropriate 5 kb size for DNA packaging into the capsid.  The 
packaging plasmid expresses VP1/VP2 in trans from the P38 promoter to provide a 





Generating an effective vector system requires starting with a competent virus 
from which to build.  Mutagenesis and selection have been performed on many 
parvoviruses to study the changes in tropism and map mutations that lead to new cell type 
infectivity.  Changes in tropism arise from many aspects of the viral genome.  For 
example, the parvovirus MVMi, which happens to be lymphotropic, can infect fibroblasts 
when two amino acids changes are made in the capsid gene that mimic the capsid of 
MVMp, as selected by plaque assays of MVMi on A9 mouse fibroblasts (20).  Other 
studies have shown that while MVMp and MVMi will not undergo lytic growth in the 
other cell’s permissive cell line, both viruses can enter and convert into double-stranded 
genomes in both cell lines, indicating that some cellular factors are limiting the virus’s 
ability to infect despite entering the cell with two different capsids (21).  The P4 promoter 
leading to the transcription of NS1 has also been shown to influence tropism (22).  These 
three leading options of capsid, non-structural protein, and P4 promoter mutations have 
become the focus of a search for a more melanoma-tropic parvovirus. 
The parvovirus LuIII has been shown to infect primary human melanoma cell 
lines, but unfortunately does not infect murine melanoma cell lines (23).  The finding that 
LuIII selectively infects human melanoma cells is what sparked this project in the first 
place, since we would need a mouse model to further develop a parvovirus-derived LuIII 
vector for humans.  While most members of the rodent parvovirus panel we have 
assembled are unable to grow in the well-characterized B16F10 mouse melanoma cell 
line, Mouse parvovirus 1a (MPV1a) was found to be the best candidate for infecting 
these cells.  As shown by a simple screening test, infection by this virus was rather 




species as LuIII and MVMp, known as rodent protoparvovirus 1 within the genus 
Protoparvovirus (24).  This is significant because many of the genomic templates, 
techniques and assays, as well as much of our understanding of parvovirus biology, stem 
from studies on MVMp, and hopefully another parvovirus derived from MPV1a in the 
same species would behave similarly.  Also, the similarity between MPV1a and LuIII 
might imply that the discoveries made with MPV1a in a murine melanoma model could 
be translated to human melanoma via LuIII.  By starting with MPV1a, we set out to 
create a parvovirus that would infect B16F10 cells just as LuIII infects human melanoma 
cells.  Parvoviral replication yields a single nucleotide mutation for every 10
4
 bases (12).  
So, with a 5000 bp genome, on average every other viral genome should have a mutation 
within it.  While many will be silent or deleterious, selection on B16F10 cells should 
occur rapidly, yielding quasi-species of mutant MPV1a parvovirus with new levels of 
melanoma infectivity.  We passaged MPV1a on B16F10 cells, infecting the cells and 
harvesting the progeny, which were then used to re-infect and select for more competent 
mutants.  This selection process was repeated five times, resulting in a polyclonal mixture 
of mutant MPV1a that was named MPV P5 (passaged five – P5).  MPV P5 became our 
window into understanding how to target parvoviruses to murine melanoma with the 
hopes of generating a vector for treatment purposes.  Genetic traits found in the MPV P5 
virus can be applied to vector system to make it as efficient as possible. 
One of the possible advantages of using a replication-competent, but non-
propagating viral vectors is that the immunostimulatory response from vector 
transduction is likely to be higher than simply expressing B7.1 in a non-replicating 




expressed to high levels.  While parvoviruses can avoid triggering some cellular defenses, 
such as Toll-like receptor 9 (TLR9) failing to detect the incoming viral DNA in 
plasmacytoid dendritic cells (25), infected cells do express some damage-associated 
molecular patterns and pathogen-associated molecular patterns (DAMPs and PAMPs).  
We predict that these DAMPs and PAMPs, in conjunction with the costimulatory 
signaling of B7.l, should result in a robust immune response to unique tumor antigens. 
While B16F10 is a useful and well-characterized model for murine melanoma, 
both in culture and transplanted into immunocompetent C57BL/6 mice, its tumor-specific 
genotype does not reflect the most frequent mutations found as drivers of human 
melanoma.  In this respect, we are fortunate to have established a collaboration with Dr. 
Marcus Bosenberg's group in Dermatology at Yale, who have provided us with a unique 
set of engineered murine melanoma cell lines that more faithfully represent the repertoire 
of driver mutations leading to human melanoma.  The Yale University Mouse Melanoma 
(YUMM) cell lines developed by the Bosenberg laboratory provide a unique opportunity 
for testing B7.1 expression in a genetically defined tumor model both in vitro and in vivo.  









 genotype.  Braf
V600E
 is a constituently active mutant.  
The second generation (denoted 2.1) utilizes a mutation that stabilizes β-catenin instead 
of the Cdkn2A knockout.  Both cell lines are transplantable into C57BL/6 mice and 
metastasize to the lungs, providing a much more realistic model than what B16F10 cells 
can provide (26).  While MPV P5 was not selected on YUMM cells, evolutionary 
advantages from growth on B16F10 cells may be equally beneficial in this other murine 




Statement of Purpose: 
 Parvoviruses may be used as an efficient vector for expressing transgenes in 
murine melanoma cell lines.  Specifically, the parvovirus MPV1a, after being passaged in 
B16F10 cells, has undergone genetic changes that improve its infectivity in melanoma 
cell lines.  These mutations can be investigated by creating chimeric viruses with MPV1a 
and MPV P5 components, and the most important components for melanoma tropism can 
be applied to the vector system to improve its functionality.  The vector system, when 
targeted to melanoma, can express immune-stimulatory signals such as B7.1 to generate 
an immune response against the tumor. 
 
Aims: 
1.) Clone and sequence parental MPV1a strain and resulting MPV P5 mutants 
2.) Analyze differences between the two sequences to isolate potential enabling 
mutations for melanoma infectivity 
3.) Create chimeric viruses by combining MPV1a and MPV P5 sequences to isolate 
mutations responsible for increased infectivity in melanoma cells 
4.) Transfer enhancing mutations into the parvoviral vector system 
5.) Construct GFP-B7.1 transgene in the vector system 
6.) Investigate expression of transgene in melanoma cell lines with vector 
transduction 
7.) Perform in vivo experiments with the vector system and monitor for a tumor-





Selection of MPV1a on B16F10 Cells 
 Performed by Peter Tattersall, the selection process occurred with plated B16F10 
cells infected with MPV1a virus.  After ~3 days, cells were harvested, spun down, and 
resuspended in Tris/EDTA (TE) buffer pH 8.7.  The sample was rapidly frozen in dry ice 
and thawed on ice three times to release virus particles from the cells.  After 
centrifugation, an aliquot of the supernatant containing the virus was applied to a fresh 
culture of B16F10 for re-infection.  This process was repeated for a total of five times.  
The resulting virus was named MPV P5 for the five passages it underwent on B16F10 
cells. 
Viral sequencing 
 I performed the PCR cloning and sequencing of the viral genomes.  Fragments of 
the viral genome were amplified with PCR.  The parental MPV1a and MPV P5 viruses 
were denatured at 95°C for 10 minutes.  Primers were designed from the start of NS1 to 
the end of VP1 and from the start of VP2 to the end of VP2.  Additional primers were 
designed from the start of VP2 to the end of the 3’ untranslated region.  PCR was done 
with high fidelity Phusion polymerase.  A-tailing of the PCR product was performed with 
Biolabs Taq DNA polymerase.  The product was incorporating into either Topo pCR 2.1 
or NEB pMiniT vectors and transformed into E. coli.  All reactions and procedures were 
carried out according to the manufacturers' instructions.  Plasmids were then sequenced 
by using proprietary primers for the respective cloning vectors at the Keck Sequencing 






 I performed the subcloning of viral sequences.  The NS1/NS2/VP1 sequence was 
isolated by digestion with PmeI and SacI restriction enzymes.  The VP2 sequence was 
isolated by digestion with SacI and PacI.  Chimeras were formed by ligating the 
appropriate fragments and the MVMp infectious clone backbone with NEB quick ligase 
and transforming into Agilent SURE-2 supercompetent cells.  Terminal hairpin lengths 
were confirmed with AflIII digests. 
Viral production 
 I performed the production of the viral chimeras.  They were grown in 293T cells 
following transfection with polyethylene imine (PEI).  2x10
6
 293T cells were plated in 
100mm dishes the day before transfection.  Each dish was treated with the transfection 
mixture of 4ug infectious clone DNA, 6ug pXX6-80 helper plasmid, and 25ul PEI.  Cells 
were harvested after 72 hours, suspended in 500ul TE pH 8.7 per plate, lysed by 
repetitive freeze/thaw cycles, and the cellular debris was discarded after centrifugation.  
Virus production was confirmed using a hemagglutination assay where 1% guinea pig red 
blood cells are mixed with increasing dilutions of viral extract.  Virus extract with high 
titers will agglutinate the RBCs and prevent them from settling to the bottom of the well, 
even at high dilutions.   
Virus purification and quantification 
Virus purification was achieved via ultracentrifugation in 15, 35, 45, and 55% 
iodixanol gradients, spun at 35,000 rpm for 18 hours.  The gradients were fractionated 
starting at the highest density of 55% iodixanol.  Samples were taken from each fraction 




Proteinase K, and 10% SDS sequentially and run in an alkaline 1.4% agarose gel for 4 
hours.  The gel was washed in denaturing and neutralizing solutions before overnight 
transfer to Bio-rad Zeta Probe blotting paper.  After crosslinking the DNA to the blotting 
paper with the UV stratalinker, the blot was probed with 
32
P-DNA generated by Klenow 
polymerase random hexanucleotide amplification with 
32
P-dATP with viral DNA 
templates.  The radioactivity was detected in a GE Typhoon scanner and the bands 
quantified using imageQUANT software.  Band intensity was compared to known 
standards loaded in the Southern blot to calculate the number of full length viral genomes 
per volume of sample. 
Viral analysis 
 The infectivity of the viruses and chimeras were assessed via flow cytometry.  
2x10
5
 B16F10 cells were seeded into 6-well plates in Gibco DMEM media with 5% fetal 
bovine serum (FBS) and glutamine, penicillin, and streptomycin.  One day after seeding, 
the cells were infected with the virus diluted into 1ml of the same media with only 1% 
FBS.  After four hours, 1ml of DMEM with 9% FBS was added to return the media to the 
normal 5% FBS ratio.  Twenty-four hours after the initiation of infection, the cells were 
harvested with trypsin, fixed in 1% paraformaldehyde, permeabilized with 0.5% Triton, 
blocked in 10% normal goat serum in PBS, stained with mouse α-NS1 mAb (CE10B10, 
ref (27)) in the blocking solution, and incubated with Biolegend goat α-mouse IgG 
DyLight 488 secondary.  Flow cytometry was performed on a MACSQuant Analyzer 10, 
set to record 10,000 events.  The positive gate was set so that 0.5% of the uninfected, 






 I performed the creation of the GFP-B7.1 transgene by following the Cold Spring 
Harbor Protocol by Szymczak-Workman et al (28).  Primers were designed to amplify 
either GFP with the picornavirus 2A tail or 2A preceding B7.1.  Two-step PCR generated 
the final GFP-2A-B7.1 product and it was cloned into the Topo pCR 2.1 plasmid.   
Vector construction 
 I performed the modifications to the previous vector system to include the new 
GFP-B7.1 transgene and incorporate the MPV P5 NS1/NS2 sequence.  Cloning was 
performed with restriction enzymes, quick ligase, and SURE-2 supercompetent cells. 
Vector production 
 I performed the production of the GFP-B7.1 vector, which was created by a triple 
transfection of 2μg vector genome, 4μg packaging plasmid expressing VP1/VP2, and 6μg 
helper plasmid with adenovirus genes.  After 72 hours, the cells were harvested and the 
vector was purified and quantitated as previously described.  
Vector analysis 
 I analyzed the GFP-B7.1 vector with Western blots, fluorescence microscopy, and 
flow cytometry.   
 The Western blot was performed with A9 cells transfected with the GFP-B7.1 
vector DNA by Superfect.  Cells were harvested in lysis buffer containing protease and 
phosphatase inhibitors after 48 hours.  The samples were boiled and the protein levels 
were calculated with a BCA assay.  Equal amounts of protein were run on an SDS-PAGE 
gel and transferred to a Hybond ECL membrane, then probed with rabbit α-GFP primary 




 Fluorescence microscopy was performed with both vector DNA transduction by 
Superfect in A9 cells for 48 hours and vector particle transduction in B16F10 cells with 
20,000 genomes/cell for 24 hours.  Slides were fixed with 2.5% paraformaldehyde in 
PBS +/+, neutralized with ammonia chloride, blocked in 10% normal goat serum in PBS 
+/+, stained with R&D systems goat α-mouse B7.1 pAb, Invitrogen donkey α-goat IgG 
Alexa Fluor 594, and DAPI.  Images were taken on a Zeiss Axio Imager M2 fluorescence 
microscope using the 20x and 40x objectives.  Control slides of cells infected with virus 
rather than vector were treated similarly, but were permeabilized with 0.1% Triton, and 
stained with mouse α-NS1 mAb and goat α-mouse IgG DyLight 594.   
 Flow cytometry analysis of the vector was performed using the previously 
described flow cytometry protocol, however the samples were not permeabilized and no 





Analysis of Evolving MPV1a DNA Sequences 
 This project required the selection of MPV1a mutants, analysis of the genetic 
changes that occurred during expansion on B16F10 murine melanoma cells, isolation of 
the mutations that improved melanoma tropism, and their application to the vector 
system.  Figure 4 shows the number of cells positive for viral infection at 24 hours with 
different parvoviruses at varying multiplicities of infection.  A cell was considered 
positive for infection based on antibody staining for the viral protein NS1 analyzed by 
flow cytometry.  Four viruses were used: MVMp, LuIII, MPV1a, and MPV P5.  MVMp, 
LuIII, and MPV1a were standard stocks of virus used in the laboratory, while MPV P5 
was generated by the polyclonal passage of MPV1a in B16F10 cells.  At the highest 
multiplicity of infection with 5000 viral genomes per seeded cell, MVMp and LuIII 
infected <2% of the cells at 24 hours.  MPV1a was more infectious with 16% of cells 
staining positive for NS1, while MPV P5 infected 74% of cells and led to moderate 
amounts of cell death and debris noticeable by microscopy.  The nearly five-fold increase 
in 24 hour infection rates between MPV1a and MPV P5 prompted the investigation of 
genetic changes responsible for the increased tropism. 
 Before progressing to sequencing, MPV1a and MPV P5 were tested in the 
YUMM cell lines.  While MPV P5 was selected in the classic murine melanoma B16F10 
cell line, the YUMM cell lines will be used for in vivo experiments to allow for 
immunologic study, and express the most common drivers of melanomagenesis in the 























24 infection in the YUMM cell lines as compared to B16F10.  There was a 2-fold 
reduction in initiation of infection at 24 hours between MPV P5 in B16F10 as compared 
to the YUMM cell lines.  While not as infectious in YUMM cells compared to B16F10, it 
is clear that MPV P5 infects each of the YUMM cell lines, suggesting that passage in 
B16F10 cells selected for melanoma-specific “generalists”, rather than for mutations 
specific for adapting to a host cell with the genotype of B16F10.  It is also difficult to 
directly compare the percentage of positive cells due to the fact that different cell lines 
divide at different rates and S phase is required for the cell to become infected in those 24 
hours.  However, since it appeared that MPV P5 could infect each of the YUMM cells, 
we proceeded with our investigation of the genetic changes found in this virus. 
 Genetic analysis was performed by PCR amplification of viral DNA, ligation into 
cloning plasmids, and sequencing.  Figure 6 shows the predicted protein sequence 
differences in NS1 between the published MPV1a sequence on GenBank (U12469), the 
parental strain of MPV1a used for selection in B16F10 cells, and the MPV P5 virus 
isolated after passaging.  NS1, NS2, and VP1 sequence was analyzed within an 
approximate 2.6 kb amplified region.  Clones are named from the originating virus stock, 
sample number, cloning plasmid used, and the date.  The NS1 region was notable for one 
amino acid change found in all MPV P5 clones – L575S.  The two mutations I206M and 
S529N were found in a majority of MPV P5 NS1 clones.  All NS1 mutations were found 
before the start of NS2.  Surprisingly, the mutations found in MPV P5 are identical to the 
GenBank sequence but differ from the parental strain of MPV1a used in the selection 











occurred within the fragment, but were not found in any known regions of importance, 
such as the NS1/NS2 splice site, localization sequences, P4 promoter, or P38 promoter.  
Mutations found only in one sample of the MPV1a parental or MPV P5 sequencing 
results were considered as PCR errors, sequencing errors, or random un-selected viral 
mutations and were not included in the analysis.  With three amino acid mutations found 
in NS1, the remaining VP2 gene was sequenced as well. 
 Figure 7 shows the VP2 protein sequence mutations between the published 
MPV1a sequence on GenBank (U12469), the parental strain of MPV1a used for selection 
in B16F10 cells, and the resulting MPV P5 virus after passaging.  As seen with the NS1 
results in Figure 7, the MPV1a parental stain does not match the GenBank sequence.  
Only one of the twelve sequenced MPV1a parental clones matched GenBank in the VP2 
region.  Among the MPV P5 clones, clone “TR” denotes a nonfunctional MPV P5 VP2 
clone isolated prior to my project that was never successfully used as an MVMp vector 
packaging capsid.  Clone “TR” matches the GenBank sequence and one of the twelve 
MPV1a clones.  Of the twelve clones that I isolated and sequenced, one clone matched 
the MPV1a parental strain.  The remaining eleven clones exhibited varying combinations 
of eight mutations in the VP2 region.  Three amino acid mutations occurred early in VP2 
before the poly-glycine flexible region.  Notable are the last two mutations -- S348N or 
R349K -- because most of the MPV P5 clones appear to have one of these mutations, but 
never both.  They are also unique because of all of the amino acid mutations found in the 





The summary of mutations found between MPV1a and MPV P5 are listed in 
Figure 8.  The localization of amino acid mutations in either NS1 or VP2 forms the basis 
of the following experiments, in which chimeric viruses are created with different 
components from NS1/NS2/VP1 and VP2.  The 3’ untranslated region was identical in all 
MPV1a parental and MPV P5 clones, and only differed from the GenBank sequence by 
three nucleotides.  The only parts of the virus that was not evaluated was the terminal 
hairpins, which tend to be conserved and are difficult to clone and sequence.  With the 
conclusion of this section, there are enough data and viral sequences to begin 








Figure 4 – Infection of B16F10 Cells with Panel of Parvoviruses 
 
B16F10 cells were infected with varying titers of parvovirus for 24 hours.  Cells were 
fixed, permeabilized, stained for NS1, and analyzed by flow cytometry.  Stained, 
uninfected cells were used as the negative control to set the threshold for positive 





























Figure 5 – Infection of YUMM cell lines with MPV1a and MPV P5 
 
YUMM cell lines were infected with MPV1a and MPV P5 for 24 hours.  Cells were 
fixed, permeabilized, stained for NS1, and analyzed by flow cytometry.  Stained, 
uninfected cells were used as the negative control to set the threshold for positive 
cells.  B16F10 cells were used as a positive control for comparison.  Each sample was 









































































Cell line and virus 















NS1 Reading Frame Codons 
Sample 206 529 575 
MPV1a Published GenBank Seq. M N S 
MPV1a #01 Topo (10-20-2011) I S L 
MPV1a #02 Topo (10-20-2011) I S L 
MPV1a #03 Topo (10-20-2011) I S L 
MPV P5 #01 Topo (10-20-2011) I N S 
MPV P5 #04 NEB (09-19-2014) M N S 
MPV P5 #07 NEB (09-19-2014) M S S 
MPV P5 #08 NEB (09-19-2014) M N S 
MPV P5 #09 NEB (09-19-2014) M N S 
MPV P5 #10 NEB (09-19-2014) I N S 
MPV P5 #12 NEB (09-19-2014) I N S 
 
MPV1a consensus  MPV P5 mutation 
 
Figure 6 – Analysis of Coding Mutations found in NS1 
 
Three clones from MPV1a and seven clones from MPV P5 were sequenced and 
compared to the published MPV1a sequence in GenBank (U12469).  Coding 
mutations found in more than a single clone were included in the table.  NS2 and VP1 
protein sequence was identical between MPV1a and MPV P5.  Red shading indicates 
the consensus sequence from the parental strain of MPV1a.  Green shading indicates a 











VP2 Reading Frame Codons 
Sample 8 11 12 54 57 70 348 349 
MPV1a Published GenBank P G S R S M S R 
MPV1a #01 (10-01-2014) S R N K G I S R 
MPV1a #02 (10-01-2014) S R N K G I S R 
MPV1a #03 (10-01-2014) S R N K G I S R 
MPV1a #04 (10-01-2014) S R N K G I S R 
MPV1a #05 (10-01-2014) S R N K G I S R 
MPV1a #06 (10-01-2014) S R N K G I S R 
MPV1a #07 (10-01-2014) S R N K G I S R 
MPV1a #08 (10-01-2014) S R N K G I S R 
MPV1a #09 (10-01-2014) P G S R S M S R 
MPV1a #10 (10-01-2014) S R N K G I S R 
MPV1a #11 (10-01-2014) S R N K G I S R 
MPV1a #12 (10-01-2014) S R N K G I S R 
MPV P5 clone “TR” (6) P G S R S M S R 
MPV P5 #01 (09-19-2014) P G S R S M N R 
MPV P5 #02 (09-19-2014) S G N K G I N R 
MPV P5 #03 (09-19-2014) S R N R S M N R 
MPV P5 #04 (09-19-2014) S R N K G I S K 
MPV P5 #05 (09-19-2014) P G S K G I S K 
MPV P5 #06 (09-19-2014) S R N K G I S R 
MPV P5 #07 (09-19-2014) P G S R S M S K 
MPV P5 #08 (09-19-2014) S G N R S M N R 
MPV P5 #09 (09-19-2014) S R N R S M S K 
MPV P5 #10 (09-19-2014) S G N K G M N R 
MPV P5 #11 (09-19-2014) S R N K G I S K 
MPV P5 #12 (09-19-2014) S R N R S M S R 
 
MPV1a consensus  MPV P5 mutation 
 
Figure 7 – Analysis of Coding Mutations found in VP2 
 
Twelve clones from MPV1a and twelve clones from MPV P5 were sequenced and 
compared to the published MPV1a sequence in GenBank (U12469).  Coding 
mutations found in more than a single clone were included in the table.  “TR” clone is 
included as a nonfunctional VP2 gene used previously.  Red shading indicates the 
consensus sequence from our parental strain of MPV1a.  Green shading indicates a 








Hairpins NS1 NS2 VP1 VP2 3' UTR 
Amino acid mutations n/a 3 0 0 8 n/a 
Silent DNA mutations unknown  12 0  4  5 0 
 
Figure 8 – Summary of Mutations between MPV1a and MPV P5 
 
Coding mutations are located only in the NS1 and VP2 genes.  Silent mutations were 
also present, although not in any known splice sites, promoter regions, or localization 
sequences.  The 3’ untranslated region (UTR) was constant between MPV1a and MPV 






Analysis of MVMp : MPV1a : MPV P5 Chimeras 
 Using the sequencing data, chimeric parvoviruses were assembled to assess the 
differences between the NS1 and VP2 mutations.  The infectious clones created from 
MPV1a and MPV P5 served as controls, as they should perform similarly to the 
polyclonal stocks of MPV1a and MPV P5 analyzed by sequencing.  By creating chimeras 
between MPV1a and MPV P5, the important mutations for B16F10 tropism were 
isolated.  Figure 9 illustrates the construction process.  During the sequencing of the 
MPV1a and MPV P5 viruses, restriction sites were added to the fragments to allow for 
reconstruction.  An engineered backbone of the MVMp virus is used as the starting point 
due to its many built-in cloning sites and assays.  The 3’ UTR and hairpins are MVMp in 
all of the chimeras, with the NS1/NS2/VP1 and VP2 regions being replaced with MPV1a 
or MPV P5 sequence.  The naming convention used for the remainder of this thesis is as 
follows: the first letter of the chimeric virus name denotes the NS1/NS2/VP1 origin, with 
“M” and “P” indicating MPV1a and MPV P5 respectively.  The hyphen serves as the 
junction between NS1/NS2/VP1 and VP2.  The second letter in the name denotes the 
origin of VP2 in the same manner of “M” or “P.”  Since the NS1/NS2/VP1 sequencing 
provided an overwhelming consensus, either MPV1a #1 or MPV P5 #8 was used in all 
constructs.  In the VP2 region, MPV1a #1 was used as the consensus for MPV1a.  MPV 
P5 had a variety of sequences in the VP2 region, so three clones were chosen.  To 
maximize the number of mutations screened, and to include S348N or R349K, MPV P5 
#1 and #7 were chosen.  MPV P5 #11 was also chosen to see if S348N was sufficient on 
its own to improve infectivity.  Part A shows the insertion of MPV1a or MPV P5 




MVMp and P – MVMp.  Part B depicts the insertion of VP2 from either MPV1a or MPV 
P5 into the intermediates from Part A.  The table gives the name and specific amino acid 
changes for each chimera.  Prior to producing large quantities of the chimeric viruses, a 
screening experiment was performed with P – P1 and P – P7, where their DNAs were 
transfected into B16F10 cells with Superfect.  After two rounds of splitting the cells as 
they became confluent, the culture’s viability crashed, encouraging us to produce all of 
the chimeras since P – P1 and P – P7 seem to cause lytic infection. 
 Each chimera was produced by transfection into 293T cells with PEI.  The 
transfections to produce chimeras with all sequence from either MPV1a or MPV P5 
produced the most virus.  The chimeras with alternating MPV1a and MPV P5 
components produced a moderate amount of virus.  The chimeras with MVMp VP2 
sequence produced very little virus.  After calculating the titer of each chimera by 
Southern blot, they were tested on B16F10 cells.  Figure 10 shows the results from 
testing the chimeras.  The percentage of B16F10 cells positive for viral infection at 24 
hours after infection with polyclonal mixtures of MPV1a or MPV P5 are compared to the 
panel of chimeras.  The experiment was performed in the same manner as Figure 4.  
Notable is the poor infectivity with MPV1a virus, possibly because this was an older 
virus stock.  As for the chimeras, the chimeras with the VP2 region from MPV P5 
performed the best, regardless of the NS1/NS2/VP1 region.  At a multiplicity of 5000 
genomes per seeded cell, M – P1 infected 5.9% of cells and P – P1 infected 6.3%.  MPV 
P5 infected 27% of cells.  The chimeric intermediates with VP2 from the MVMp 
backbone performed the worst, which correlates with them being the most difficult virus 




Given the complicated nature of testing all of the chimeras, a smaller panel was 
selected in order to optimize timing, processing, and analysis.  Figure 11 repeats the 
experiment performed in Figure 10 but focuses on the VP2 region from MPV P5 #1 with 
S348N.  Neither clonal chimera performed as well as the polyclonal virus stock from 
which it was derived.  At the highest titers of 5000 genomes per cell, M – M1 infected 
5.4% of cells at 24 hours, while MPV1a infected 15.8%.  At the same titer, P – P1 
infected 44.7% of cells while MPV P5 infected 74.1%.  The important component of the  
P – P1 chimera appears to be the VP2 region, which increases the infectivity of M – M1 
from 5.4% to 34.1% in M – P1.  The NS1/NS2/VP1 plays a minor role in the infectivity 
of MPV P5, advancing M –P1 from 34.1% to 44.7% in P – P1.  There still remains a 2-3 
fold difference between the polyclonal stocks of MPV1a and MPV P5 and their cloned 
versions in the MVMp backbone.  It is possible that we either picked the inefficient 
clones to use, needed to incorporate more sequence from the 3’ UTR/hairpins, or that the 
production of the chimeras in 293T cells differed from the way that MPV1a and MPV P5 
were produced in 324K and B16F10 cells, respectively. 
 Figure 12 shows the results from testing the P – P1 chimera made in different cells 
lines.  One of our major concerns was that the infectivity might vary between P – P1 and 
MPV P5 due to differential processing by the cells that produced them.  To test this 
hypothesis, the P – P1 chimera was produced in different cell lines and compared to MPV 
P5.  The first sample is the P – P1 chimera, made by transfection in 293T cells, which was 
used in all previous experiments.  It is clonally derived from plasmid DNA and 
undergoes a single cycle of growth in 293T cells over 72 hours and accumulates 




subjected to an important late maturation step.   The next sample is the same chimera 
made in B16F10 cells by transfection with PEI.  The transfection had a low yield, but 
virus was collected at 72 hours.  The third sample is the P – P1 chimera from 293T cells 
but expanded in B16F10 cells.  The virus was collected after the cells crashed and is no 
longer inherently clonal since selection and multiple rounds of infection occurred.  The 
last sample is the polyclonal stock of MPV P5 that has been used throughout all of the 
figures and was grown in B16F10 cells.  At the titer of 5000 genomes per cell, P – P1 
from 293T cells approaches 56.2% of the infectivity of MPV P5, which is consistent with 
the 2-fold difference seen in the previous figure.  After passaging in B16F10 cells, P – P1 
is 81.3% infectious as MPV P5.  The results from P – P1 made in B16F10 cells through 
transfection were difficult to interpret since the titer may be inaccurate given the small 
amount of dilute virus produced.  Overall, passaging the chimera in B16F10 cells 
increased the infectivity partially, but did not obtain the rate shown by MPV P5.  Given 
that production of virus by transfection in 293T cells was not overly detrimental to its 
functionality, we decided to use the sequences from P – P1 to improve the melanoma 









NS1 Codon VP2 Codon 
Name 206 529 575 8 11 12 54 57 70 348 349 
M-M1 I S L S R N K G I S R 
M-P1 I S L P G S R S M N R 
M-P7 I S L P G S R S M S K 
M-P11 I S L S R N K G I S K 
P-M1 M N S S R N K G I S R 
P-P1 M N S P G S R S M N R 
P-P7 M N S P G S R S M S K 
P-P11 M N S S R N K G I S K 
 
 
Figure 9 – Construction of Chimeric MPV1a and MPV P5 Viruses 
 
Chimeric viruses were created from the NS1/NS2/VP1 and VP2 fragments isolated 
from MPV1a and MPV P5.  Part A shows how the NS1/NS2/VP1 genes were first 
inserted into an MVMp genome backbone.  Part B shows how VP2 genes were added 
to Part A, resulting in eight different chimeras from one MPV1a VP2 and three MPV 
P5 VP2 variants.  The table lists the name of each chimera and shows the differences 
between each construct.  Naming is based on the origin of each fragment – M for 
MPV1a and P for MPV P5.  The first letter denotes the NS1/NS2/VP1 fragment, while 







Figure 10 – Infection of B16F10 Cells with Chimeric MPV1a and MPV P5 
 
B16F10 cells were infected with varying titers of virus for 24 hours.  Polyclonal 
stocks of MPV1a and MPV P5 were compared to clonal chimeras.  Cells were fixed, 
permeabilized, stained for NS1, and analyzed by flow cytometry.  Stained, uninfected 
cells were used as the negative control to set the threshold for positive cells.  Each 






























































































Figure 11 – Infection of B16F10 Cells with P – P1 Chimera Components 
 
B16F10 cells were infected with varying titers of virus for 24 hours to repeat the 
previous figure with fewer variables and complexity.  Polyclonal stocks of MPV1a 
and MPV P5 were compared to components found in P – P1.  P – P1 was used due to 
its relatively high infectivity relative to the other chimeras in the previous figure.  
Cells were fixed, permeabilized, stained for NS1, and analyzed by flow cytometry.  
Stained, uninfected cells were used as the negative control to set the threshold for 






































Figure 12 – Infection of B16F10 Cells with P – P1 Produced in Different Cell Lines 
 
The chimera P – P1 was originally produced by a single round of replication in 293T 
cells.  To test if 293T cells resulted in differential final processing of the mature 
virion, the chimera was also produced in B16F10 cells by transfection.  A third sample 
was produced by taking the chimera from 293T cells and expanding it in B16F10 cells 
for multiple rounds of infection before harvesting.  These three different modes of 
producing P – P1 were compared to the MPV P5 stock that was grown in B16F10 
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Further Vector Development 
 The previous parvoviral vector system used predominantly MVMp sequence and 
expressed only GFP.  To upgrade this vector, we decided to first express both GFP and 
B7.1 to make it immunostimulatory and then add MPV P5 components to improve its 
tropism for melanoma cells.  Figure 13 shows the construction of the new vector system.  
Part A shows how the picornavirus sequence 2A was used to combine expression of GFP 
and B7.1.  The sequence 2A stalls translation of mRNA into protein.  The stalling process 
prevents peptide bond formation, and the first protein product linked to the 2A sequence 
is ejected from the ribosome.  Translation continues, producing the second peptide 
independently from the first.  As a result, two polypeptides can be expressed from one 
mRNA molecule without requiring multiple promoters or a bulky internal ribosome entry 
site (IRES).  To incorporate the 2A sequence, two-step PCR was used to create the GFP 
sequence without a stop codon, linker picornavirus 2A sequence, and B7.1.  Once the 
GAB (GFP – 2A – B7.1) construct was created, it was combined with a GFP-only vector 
system to create the intermediate in Part B.  The vector system uses an early stop codon 
in VP1 to block its production, leading to expression of the transgene alone, once NS1 is 
produced and activates the P38 promoter.  The intermediate construct was very large due 
to the increased length of B7.1 and the remaining LuIII VP2 stuffer DNA that was used 
to bring the original GFP-only construct up to full viral genome length (see previous 
Figure 3).  Part C has the removal of the LuIII virus stuffer sequence that is replaced by 
the MVMp 3’ untranslated region with two internal repeats, as normally found in MVMp.  
The length of GAB is approximately the same as VP2, so no additional non-specific viral 




the vector and stable capsid arrangement.  Part D shows the final product, which has the 
NS1/NS2 region found in the chimera P – P1.  A mutant version of the B7.1 vector, 
named GAmB, that is incapable of costimulatory signaling due to the Y201A mutation 
described by Guo and colleagues (29) was also created and produced in the same manner. 
 Once the DNA for the vector system was produced, a preliminary test of its 
function was performed by plasmid transfection before undertaking the process to 
produce vector particles.  Figure 14 shows a western blot probed for GFP.  A9 cells were 
transfected using Superfect with either no DNA, vector DNA encoding GAB, or vector 
DNA encoding GFP-only.  Cells were collected, lysed, and run on an SDS-PAGE gel and 
transferred to a Hybond ECL membrane, then probed with rabbit α-GFP primary pAb 
and α-rabbit HRP as secondary.  The mock transfection showed no bands (Lane 1).  Lane 
2 shows GFP expression by the GAB vector construct.  Lane 3 shows GFP expressed by 
a GFP-only vector, as a positive control.  GFP expressed by the GAB vector should be 21 
amino acids larger than normal GFP due to the tail created by the 2A linker sequence, 
while the GFP-only vector does not have any additional peptide attached to it.  As a 
result, the GFP band in GAB runs slightly larger than the normal 27 kDa GFP shown in 
the GFP-only lane.  No GFP band was seen at 82 kDa, which would be expected if the 27 
kDa GFP and 55 kDA B7.1 were linked together.  A western blot probed for B7.1 proved 
unsuccessful after several attempts, possible because the antibody works well on intact, 
non-permeabilized cells, but is incapable of staining denatured, lysed samples.  
Therefore, intact fixed cells were examined for B7.1 expression by immunofluorescence. 
Figure 15 shows A9 cells transfected with GAB vector DNA using Superfect to 




secondary were applied to fixed, non-permeabilized cells.  The cells were examined by 
fluorescence microscopy, where blue represents DAPI staining of nuclear DNA, green 
for GFP, and red for B7.1.  The fourth image shows the merged result of all three 
previous images.  The DAPI image shows multiple nuclei of A9 cells on the spot slide.  
The GFP image highlights a single cell that has the majority of its intensity at the center 
of the cell.  The B7.1 image shows staining on the outside of the cell clearly marking its 
dentritic-like extensions.  Finally, the merged image emphasizes the blue nucleus, GFP 
on the inside of the cell, and B7.1 exposed on the surface. 
Given the success of the western blot in Figure 14 confirming slightly larger-than-
normal GFP and Figure 15 showing B7.1 expression on the cell surface, we proceeded to 
form vector particles by packaging the vector DNA in the MPV P5 capsid. 
 Figure 16 shows the construction of the vector particle.  Three plasmids were used 
in a triple transfection to generate dual transgene vector particles in 293T cells.  The first 
plasmid, named P – P1 GAB 2R vector, has an MVMp backbone (hairpins and 3’UTR 
with two repeats) with the MPV P5 NS1/NS2 from the P – P1 chimera, a truncated VP1 
sequence from LuIII, and the GFP-B7.1 transgene.  This plasmid, when expressed, 
creates NS1/NS2 from the P4 promoter.  NS1 drives the P38 promoter in the vector 
creating the GFP and B7.1 proteins.  NS1 also drives the P38 promoter in the P – P1 
packaging plasmid.  This plasmid has the C-terminal sequence of LuIII NS1/NS2 that 
includes the P38 promoter, followed by the VP1/VP2 genes from the P – P1 chimera.  
The poly-adenylation signal from rabbit ß-globin replaces the viral 3’UTR in order to 
eliminate any homology between this region in both the vector and the packaging 




and encapsidate the vector DNA that is incapable of making capsid.  The third plasmid 
encodes the viral genes VA, E2A, and E4 from adenovirus that have been shown to 
improve AAV vector formation (30) and also improves parvoviral vector trans-
encapsidation as well.  The diminished sequence identity between the plasmids 
suppresses recombination and reduces the risk of generating propagation-competent 
virus. 
Once the vector particles were produced, they were first tested on B16F10 cells 
seeded on microscope slides.  Previous immunofluorescence images used A9 cells, 
whereas here we are testing B16F10 cells with vector particles packaged in the P – P1 
capsid.  B16F10 cells were incubated with 20,000 vector particles per cell for 24 hours.  
Figure 17 shows microscopy images of B16F10 cells that were uninfected, infected with 
P – P1, or infected with GAB.  In Part A, the cells were permeabilized and stained for 
NS1 in red.  The uninfected control shows no expression of GFP or NS1.  P – P1 shows 
expression of NS1 but no GFP.  The GAB vector shows expression of both GFP and 
NS1.  This confirmed that cells infected with the vector could be identified with GFP as 
an alternative to permeabilizing and staining for NS1.  Another set of spot slides as 
shown in Part B were prepared in parallel and were fixed but not permeabilized.  They 
were stained with goat α-B7.1 pAb and red α-goat secondary.  Uninfected cells and P – 
P1 infected B16F10 cells show neither GFP nor B7.1, while GAB-infected cells express 
both.  Since the GAB vector functioned well, we decided to quantitate the transduction 
rate of the vector particles. 
 Figure 18 shows the transduction rate of the P – P1 GAB vector compared to 




constructs, the rates should be the same.  B16F10 cells were exposed to 20,000 genomes 
per cell of either the vector or chimera for 24 hours.  Vector-transduced cells were 
analyzed for GFP signal, while cells infected by the chimera were fixed and stained for 
NS1.  Rates of expression in the cells were 33% and 23% for the vector and chimera, 
respectively.  The chimera values showed considerable variation, such that no significant 








Figure 13 – Production of the GFP-B7.1 Vector Construct 
 
An MVMp GFP-expressing vector was altered to express GFP and B7.1 with the 
MPV P5 NS1/NS2 region from the P – P1 chimera.  Part A shows how two-step PCR 
combined GFP and B7.1 into a single reading frame with a picornavirus 2A linkage.  
The 2A sequence stalls the ribosome during translation, leading to separate GFP and 
B7.1 peptides despite a single mRNA transcript.  This construct of GFP, 2A, and B7.1 
is named “GAB.”  Part B shows the original vector system with an early VP1 stop 
codon to promote transgene expression and the replacement of GFP in the vector by 
GAB.  Part C shows the removal of LuIII stuffer DNA used to bring the GFP-only 
vector to full genome length.  Part D shows the incorporation of the NS1/NS2 region 








Figure 14 – Western Blot Analysis of GFP Expression by Vector DNA Transfection 
 
A9 cells were transfected using Superfect with either no DNA, GAB, or GFP-only 
vector DNA.  Cells were harvested 48 hours later.  Staining for GFP showed no signal 
in the negative control (lane 1).  The GFP band from GAB transfection (lane 2) was 
slightly larger than the GFP-only vector positive control (lane 3) due to the additional 




Figure 15 – Fluorescence Microscopy of GAB Vector DNA Transfection 
 
A9 cells were transfected using Superfect with GAB vector DNA.  Cells were fixed 48 
hours later and stained for B7.1.  The DAPI image shows blue nuclear staining.  GFP 
expression shows green intracellular fluorescence.  B7.1 expression shows antibody 
staining of the cellular membrane in non-permeabilized cells. 







Figure 16 – GAB Vector Production 
 
Given the success of the DNA transfection in A9 cells, the GAB vector was produced 
with the VP1/VP2 genes from the P – P1 chimera.  This is achieved by a triple 
transfection with the vector genome, packaging plasmid, and an adenovirus helper 
plasmid to improve efficiency.  The vector genome generates NS1, which activates the 
P38 promoter.  VP1/VP2 from the packaging plasmid is expressed to provide the 







Figure 17 – Vector Transduction of B16F10 Cells 
 
B16F10 cells seeded on spot slides were infected with 20,000 genomes per cell of P – 
P1 chimera or the P – P1 GAB vector for 24 hours and then were fixed.  The first panel 
shows cells permeabilized and stained for NS1 in the red channel.  The uninfected 
control shows no GFP or NS1, the P – P1 chimera shows NS1 only, and the GAB 
vector produces GFP and NS1.  The second panel shows staining for B7.1 in non-
permeabilized cells.  The uninfected control and P – P1 chimera show no GFP or B7.1, 






Figure 18 – Flow Cytometry Analysis of GAB Vector Compared to P – P1 Chimera 
 
B16F10 cells were infected with 20,000 genomes per cell of the P – P1 GAB vector or 
P – P1 chimera for 24 hours and were fixed.  Cells transduced with the GAB vector 
were analyzed for GFP signal.  Cells infected with the P – P1 chimera were 
permeabilized and stained for NS1.  Each sample was performed in duplicate with 


















Construct and Signal 









 The overarching goal for this project was to create the most efficient vector for 
the transduction of immunostimulatory genes into murine melanoma cells.  To do this, 
we investigated an MPV P5 mutant parvovirus that was selected by serial passage in the 
B16F10 mouse melanoma cell line.  Multiple themes arose from this goal as we 
experimented with the MPV P5 virus and tried to make a clonal sequence that would 
perform like the polyclonal mixture from which it was derived. 
Process of Selection 
 The process of selection used in generating MPV P5 was very non-specific.  
Simply, the viral sub-species that was able to replicate and spread most rapidly would 
continue to increase in the overall proportion of the viral mixture.  While this would be 
ideal for an oncolytic vision for parvoviral treatment of melanoma, this is not the best 
suited approach for optimizing the vector system, since the vector replicates but does not 
expand in culture.  Therefore, it is possible that we have selected MPV P5 to become the 
fastest replicating, or the fastest packaged, or the fastest exported virus.   What we need is 
the virus that initiates infection the best, meaning that a low multiplicity of virus would 
cause the highest percentage of cells to become infected during a single round of 
infection.  However, the evidence suggests that we unknowingly created a virus that 
incentivized rapid expansion in cell culture. 
Analysis of MPV P5 
 The goal of analyzing MPV P5 was to extract the necessary components to make 
a functioning vector, and the VP2 region was initially our primary interest.  However, 




region in an MVMp backbone, the search was expanded to include the NS1/NS2/VP1 
regions as well.  In retrospect, the so-called “TR” clone that was used extensively before 
this project lacked one of the two VP2 mutations that have subsequently been identified 
as being important for MPV P5 tropism.   
 Early attempts at using PCR to create entire genome copies of MPV P5 were 
unsuccessful, and cloning the genome in separate halves proved to be more 
straightforward.  At this point, we contemplated using deep sequencing to get thousands 
of sequence reads, but we decided against it for several reasons.  First, after sequencing, 
we wanted to be able to use whichever sequence appeared to be the consensus.  This was 
much easier done with a few PCR products that were put into plasmids and sequenced.  
Second, deep sequencing would not show us how the mutations occurred in individual 
copies of the genome.  As we discovered that MPV P5 tended to either have S348N or 
R349K in the VP2 gene, this would have been lost in the aggregated data from deep 
sequencing.  So the decision was made to use PCR to generate clones for sequencing. 
The process of PCR presented some problems.  First, the primers were designed 
from the published MPV1a sequence in GenBank.  As a result, if the tropism-defining 
mutations were at the beginning of NS1, end of VP1, start of VP2, or end of VP2, the 
primer would mask the mutation.  Second, splitting the genome in half could mean that 
we lost the correlation of mutations in the left half that have co-evolved with mutations in 
the right half. 
Rational and Results from the MPV P5 Chimeras 
 Ideally, clonal versions of MPV1a and MPV P5 would have been generated that 




failed to be as infectious as their parents.  The idea behind generating so many chimeras 
was to isolate the necessary genetic features to incorporate into the vector.  Originally, we 
thought it would be more straightforward to clone the VP2 region directly into the 
packaging plasmid if the VP2 region was found to be the only important component.  As 
the chimeric virus data became more complicated, it became easier to clone all of the P – 
P1 components into the vector system to fit with our goal of creating the most efficient 
melanomatropic vector, rather than characterizing specific mutations responsible for the 
tropism change. 
 Since the chimeras were not as infectious as MPV P5, we questioned our decision 
not to include the MPV P5 3’ UTR or hairpins in the constructs.  For many reasons, the 
3’ UTR was largely ignored.  We knew that the UTR did not mutate from MPV1a to 
MPV P5, so that made it less interesting.  Also, the UTR had 2 internal repeats and is 
similar to the MVMp sequence in construct backbone.  The addition of difficult cloning 
sites in the MPV P5 3’ UTR was also a major deterrent.  However, now that we have the 
P – P1 chimera that still underperforms compared to its uncloned parent, we have to 
consider that it is, perhaps, more important that we originally thought.  This is reinforced 
by the fact that both M – M1 and P – P1 were unable to replicate at the rate of their 
polyclonal ancestors.  Since no changes were found between MPV P5 and its parent in 
the 3’ UTR, this region is likely important for the overall functionality of MPV1a, rather 
than increasing its infectivity specifically in melanoma cells.  The smaller internal repeats 
found in the 3’ UTR of MPV1a/MPV P5 may perform better with the chimera and vector 
genomes than the MVMp 3’ UTR.  Historically, the 3’ UTR was thought of as just a 




since a full capsid is necessary to give the mature virion its durability.  Evolutionarily, the 
internal repeats appear to be capable of expanding or shrinking in response to size 
changes in the rest of the genome.  However, there is now evidence of the 3’ UTR 
mutating and changing in length when the virus is grown in different cell lines, even 
though the genome is packaged into the same capsid, indicating that the 3’ UTR 
contributes more significantly to viral tropism than previously thought. 
 The other component that was largely ignored in this process were the terminal 
hairpins.  They are notoriously difficult to work with due to the hairpin structures 
creating problems with sequencing and cloning.  Their small size and complementarity 
means that they can be easily and undetectably deleted and are extremely difficult to 
amplify by PCR.  Also, the fact that they are strongly conserved within genera suggested 
that they are an unlikely source of variation, either between MVM and MPV1a, or 
between MPV1a and its MPV P5 derivatives.  However, just as with the 3’ UTR, the 
observation that we were unable to make M – M1 perform like MPV1a despite having a 
very strong consensus sequence indicated that some part of the genome derived from the 
MVMp backbone in the chimera is suboptimal for the overall functionality of the MPV1a 
clone. 
 A surprising detail from the sequencing was how our parental strain of MPV1a 
failed to match the published sequence.  It was even more surprising that subsequent 
selection on B16F10 cells shifted MPV P5 closer to the published sequence.  This may 
have occurred because MPV1a is a murine virus originally isolated and grown in the L3 
murine clonal T cell line and had been packaged in human 324K cells to amplify stocks 




differences seen between the published sequence and polyclonal MPV1a we sequenced.  
When selection began on murine B16F10 cells, MPV P5 may have drifted back to the 
original published sequence, except for the addition of S348N and R349K, which were 
not seen in the published sequence or the sequence we derived for the parental MPV1a.  
The lack of S348N or R349K mutations in the VP2 of the published sequence or parental 
MPV1a suggests that these changes are the most significant adaptations to efficient 
growth in murine melanoma cells. 
 The effects of VP2 surface residues has been studied in MVMp.  In MVMp, 60 
VP subunits assemble into a T=1 icosahedral particle.  The capsid polypeptides assemble 
as a repeating triangular unit bordered by 5-fold, 3-fold, and 2-fold axes.  The 5-fold axis 
is located at the pore where viral DNA is packaged into and extruded from the capsid.  
The 3-fold axis has been identified as the location of a neutralizing antibody epitope.  The 
depression at the 2-fold axis is responsible for glycan binding and has been shown to be 
important for tropism in MVM.  MVMp and MPV1a share 71.2% homology of VP2 
protein sequence (9) and we may be able to use the MVMp structure to help decode the 
MPV1a mutations.  An MVMp surface map of VP2 residues (see Figure 19A) is helpful 
to see which residues are exposed on the surface of the virion and could influence 
tropism (32).  By locating the mutations found in MPV P5, we can see if the mutated 
residues interact with known tropism-determining residues within the MVMp structure.  
To get oriented, Figure 19B shows four MVMp VP2 subunits arranged to re-construct the 
2-fold symmetry axis in PyMOL with PDB structure 1Z14.  Figure 19C enlarges the 2-
fold axis region, as outlined by the blue boxes in Figures 19A and 19B.  Of the eight VP2 




residues) would be on the surface of the virion and near the tropism-defining residues 
(shown in black text).  A limitation of this method of analysis is that there may be 
significant conformational differences between the known structure of MVMp and the 
unknown structure of MPV P5.  Although the overall structure of VP2 is predicted to be 
similar, individual residues may not align.  Not surprisingly, the known tropism-defining 
residues in MVMp are different in MPV P5 as well.  For example, residue K241, which 
appears very close to R349, is a serine in MPV P5.  Therefore, the tropism-defining 
residues shown in the figure are not the actual residues of MPV P5.  The creation of more 
chimeras with single amino acid changes could further explain the question of tropism, 
however the main objective was to use MPV P5 sequence to make a vector, so dissection 







Figure 19 – VP2 Mutation Analysis 
 
The role of VP2 in determining tropism has been extensively studied using MVMp.  
Part A is a figure from Halder & Agbandje-McKenna (31) which shows the surface 
residues of the VP2 protein exposed on the outside of the virion.  The residues 
responsible for tropism and receptor binding are clustered along the 2-fold axis of the 
triangular unit.  Part B shows how four VP2 peptides align along the 2-fold axis in 
MVMp.  The colors of the subunits are preserved in Part C, which highlights the 
proximity of mutated residue positions in MPV P5 (white text) with the known 




Creating the Vector 
 Until now, the parvoviral vectors created in our lab have expressed only one 
protein.  The use of the picornavirus 2A sequence provided a unique opportunity to fit 
two genes in a compact space without requiring an additional, bulky internal ribosome 
entry site.  The 2A sequence has been studied extensively and equipped with addition 
sequence to optimize the stalling and peptide breakage process.  This system has also 
been shown to generate a reliable 1:1 ratio of first and second products (33).  We decided 
that GFP should be the first transgene due to the reported problem of “slip-streaming” 
with the 2A sequence whereby the intracellular localization of the second product follows 
that of the first product.  By putting GFP first, it can be expressed into the cytosol, and 
the B7.1 protein can still be targeted to the cell membrane.  GFP serves as a useful 
reporter due to the extensive permeabilization required to stain for viral proteins in the 
nucleus.  Once we can confirm B7.1 signal with GFP in transduced cells by flow 
cytometry, GFP can be used as a surrogate for NS1 or B7.1, allowing us to ask more 
complex questions. 
 So far, the picornavirus 2A sequence has worked flawlessly.  Western blots 
confirmed the slightly larger GFP molecule due to the 2A tail on it, and the 
immunofluorescence of transduced cells showed intracellular GFP coinciding with 
membrane-bound B7.1 under the microscope.  The vector genome packaged well into the 
P – P1 capsid proteins at a reasonable yield.  The one major problem that remains is 
optimizing the signal for analysis by flow cytometry.  In contrast to the 
immunofluorescence results, the GFP positive cells do not appear to be staining 




protocol problem that will require optimization of the cell processing, antibodies, and 
staining parameters.     
 Adapting the P – P1 chimera into the vector system was straightforward, and we 
expected similar rates of transduction with the vector as infection with the chimera, since 
all of the chimera components were used in the vector.  MPV P5 NS1/NS2 was used in 
the vector genome, while MPV P5 VP1/VP2 was expressed from the packaging plasmid.  
The 3’ UTR and hairpins have been consistently MVMp sequence in both the chimeras 
and vector, but could be upgraded to MPV P5 sequence should they be found to be 
important in ongoing 3’ UTR experiments.   
Such improvements in vector transduction efficiency, if achieved, would allow us 
to move to more immunologic assays.  We plan to use the vector in a murine melanoma 
YUMM cell derivative that expresses the melanocyte protein GP100, a known tumor 
antigen in human melanomas, and is transplantable into mice.  This will allow us to use 
MHC I tetramer technology to measure the induction of cytotoxic T cells by vector 
transduction in vivo.  We also intend to examine whether the virus and/or the vector lead 
to cellular changes that signal the immune system through DAMPs and PAMPs.  
Conclusion 
 MPV1a virus that was grown in B16F10 cells mutated over time and became 
significantly more infectious for these cells.  By cloning and sequencing parts of the 
genome, we were able to construct a chimeric parvovirus infectious clone that was able to 
infect B16F10, albeit not as efficiently as the selected virus from which it was derived.  
The VP2 gene was the most important region for conferring B16F10 tropism.  Using the 




stimulatory molecule B7.1.  With more testing and improvement, this vector could be 
used to induce melanoma cells to express this immunostimulatory molecule, and thus 
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